Jupiter Life Line Hospitals Limited Beat Revenue Forecasts By 6.5%: Here's What Analysts Are Forecasting Next

Last week, you might have seen that Jupiter Life Line Hospitals Limited (NSE:JLHL) released its quarterly result to the market. The early response was not positive, with shares down 3.1% to ₹1,506 in the past week. It was a workmanlike result, with revenues of ₹3.9b coming in 6.5% ahead of expectations, and statutory earnings per share of ₹29.47, in line with analyst appraisals. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the current consensus from Jupiter Life Line Hospitals' five analysts is for revenues of ₹14.9b in 2026. This would reflect a reasonable 7.6% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to accumulate 6.4% to ₹32.25. In the lead-up to this report, the analysts had been modelling revenues of ₹14.6b and earnings per share (EPS) of ₹32.50 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for Jupiter Life Line Hospitals

There were no changes to revenue or earnings estimates or the price target of ₹1,771, suggesting that the company has met expectations in its recent result. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Jupiter Life Line Hospitals analyst has a price target of ₹1,850 per share, while the most pessimistic values it at ₹1,610. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of Jupiter Life Line Hospitals'historical trends, as the 16% annualised revenue growth to the end of 2026 is roughly in line with the 18% annual growth over the past year. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 19% annually. It's clear that while Jupiter Life Line Hospitals' revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Jupiter Life Line Hospitals going out to 2028, and you can see them free on our platform here..

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Jupiter Life Line Hospitals , and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.